These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15579048)

  • 41. PPAR gamma gene--a review.
    Janani C; Ranjitha Kumari BD
    Diabetes Metab Syndr; 2015; 9(1):46-50. PubMed ID: 25450819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)].
    Rousseaux C; Desreumaux P
    J Soc Biol; 2006; 200(2):121-31. PubMed ID: 17151549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation.
    Na HK; Surh YJ
    Biochem Pharmacol; 2003 Oct; 66(8):1381-91. PubMed ID: 14555212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.
    Knouff C; Auwerx J
    Endocr Rev; 2004 Dec; 25(6):899-918. PubMed ID: 15583022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components.
    Martin H
    Mutat Res; 2010 Aug; 690(1-2):57-63. PubMed ID: 20973164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S
    Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PPARgamma and its ligands: therapeutic implications in cardiovascular disease.
    Villacorta L; Schopfer FJ; Zhang J; Freeman BA; Chen YE
    Clin Sci (Lond); 2009 Feb; 116(3):205-18. PubMed ID: 19118492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can PPAR gamma ligands be used in cancer therapy?
    Rumi MA; Ishihara S; Kazumori H; Kadowaki Y; Kinoshita Y
    Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):465-77. PubMed ID: 15579013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
    Mughal A; Kumar D; Vikram A
    Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity.
    Speca S; Dubuquoy L; Desreumaux P
    J Clin Gastroenterol; 2014; 48 Suppl 1():S23-7. PubMed ID: 25291120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
    J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis.
    Voutsadakis IA
    J Cancer Res Clin Oncol; 2007 Dec; 133(12):917-28. PubMed ID: 17659359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
    Benz V; Kintscher U; Foryst-Ludwig A
    Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
    Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.